{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260529095946/en/FDA-Grants-Breakthrough-Therapy-Designation-for-Calderasib-MK-1084-an-Investigational-KRAS-G12C-Inhibitor-for-Certain-Patients-with-Newly-Diagnosed-Metastatic-KRAS-G12C-Mutant-Non-Small-Cell-Lung-Cancer-NSCLC", "message": "News view counter 766580 successfully enlarged"}